Covid vaccine development could go Omicron-and-on
Omicron-adapted boosters look good ahead of a key FDA panel, but will the virus soon outmanoeuvre them?
Another step backwards for Valneva
The group’s Covid vaccine, as well as Sanofi and Glaxosmithkline’s jab, might not reach Europe for some time.
Mitsubishi's Medicago heads for the Covid-19 booster queue
The Canadian subsidiary claims success in its pivotal trial, though capacity restraints will limit the jab’s role for now.
Bavarian Nordic goes it alone, for now
Phase 3 in RSV will begin without a partner, while decent Covid-19 booster data pave the way for pivotal development.
